Current and Potential Uses of Immunocytokines as Cancer Immunotherapy.
about
Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteA phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors.Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.Production of an active anti-CD20-hIL-2 immunocytokine in Nicotiana benthamiana.Different tissue distribution properties for glycosylation variants of fusion proteins containing the p40 subunit of murine interleukin-12.Immunocytokines for cancer treatment: past, present and future.Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulationDelivering safer immunotherapies for cancer.Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins.N-glycan engineering of a plant-produced anti-CD20-hIL-2 immunocytokine significantly enhances its effector functions.Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo.Addressing the Immunogenicity of the Cargo and of the Targeting Antibodies with a Focus on Demmunized Bacterial Toxins and on Antibody-Targeted Human Effector Proteins.Antibody-Based Targeted Delivery of Interleukin-22 Promotes Rapid Clinical Recovery in Mice With DSS-Induced Colitis.
P2860
Q28066935-399BD71E-E501-4A16-AE25-2558CE9F5975Q34548847-B3D3CABA-F89A-4F5C-AA25-2F09F1EACAB8Q35212575-C3FD38D5-19B1-41C5-AF4B-1A6A044D6EB0Q35603066-22B272C5-C6EE-4C58-B9E8-641897CAF9F0Q37559740-987DA78F-63B5-4614-8B72-A599975941CDQ37560208-3A71C78E-9E2B-4E37-BD29-0699CE44E33FQ38364462-B7497AA4-23C4-45B0-BF8E-F2B45332BCDFQ38974641-A667F6A9-E4AC-4DC1-84DD-17E95497555FQ39330984-C2606EFC-52FD-46BB-9DAF-FADABB91B235Q46721978-ED614083-3457-44E0-8075-17E5D7AA85CDQ47277628-EEDCC085-5C35-4864-B407-F95A1E435C92Q47311471-1297D2E9-A4A5-4F49-86B9-3613345A8395Q50544077-414BCB09-4455-4612-AB73-FCFE4A42479DQ50962872-CECC8FEC-C19B-44D9-9898-F2CAC326A302Q51599949-5B4D9C13-75C1-4280-8DAB-62E0E68392EA
P2860
Current and Potential Uses of Immunocytokines as Cancer Immunotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current and Potential Uses of Immunocytokines as Cancer Immunotherapy.
@en
Current and Potential Uses of Immunocytokines as Cancer Immunotherapy.
@nl
type
label
Current and Potential Uses of Immunocytokines as Cancer Immunotherapy.
@en
Current and Potential Uses of Immunocytokines as Cancer Immunotherapy.
@nl
prefLabel
Current and Potential Uses of Immunocytokines as Cancer Immunotherapy.
@en
Current and Potential Uses of Immunocytokines as Cancer Immunotherapy.
@nl
P2860
P356
P1476
Current and Potential Uses of Immunocytokines as Cancer Immunotherapy.
@en
P2093
Paul M Sondel
Stephen D Gillies
P2860
P304
P356
10.3390/ANTIB1020149
P577
2012-07-01T00:00:00Z